With continuously increasing incidence rates, about 300 million people suffer from asthma worldwide. The reported prevalence of asthma among the Saudi population varies from 4% to 25%.\[[@ref1][@ref2][@ref3][@ref4]\] However, due to the lack of solid and precise diagnostic criteria, reports of asthma prevalence vary and are not always accurate.\[[@ref5][@ref6][@ref7]\]

It is thought that 60% of asthma cases are inherited. Other risk factors include tobacco exposure, occupational exposure, air pollution, house dust mite, cesarean section, severe respiratory tract infection, and obesity.\[[@ref6][@ref8]\]

Asthma can have severe long-term sequelae and even patients with moderate or mild asthma may experience airway remodeling leading to severe airway obstruction later in life.\[[@ref9]\]

In multiple studies, asthma patients were found to have lower quality of life (QoL) in terms of functionality and productivity.\[[@ref10][@ref11]\] This highlights the importance of proper asthma management to provide symptomatic relief, prevent the development of permanent airway injury, and improve QoL of asthma patients.\[[@ref5][@ref7][@ref9]\]

Although there have been great improvements in the field of asthma care, level of asthma control is still considered suboptimal in many countries.\[[@ref7][@ref10][@ref11][@ref12]\]

Despite the presence of large information on the level of asthma control and management in many sites, data from the Middle East are still insufficient, and only very few studies with relatively small samples are published. Moreover, demographic and disease-related factors associated with poor asthma control in this area are still not well documented.\[[@ref13][@ref14]\]

Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population (ESMAA) study\[[@ref15]\] was carried out to assess the level of asthma control as per the Global Initiative for Asthma (GINA) 2012\[[@ref16]\] in addition to potential factors affecting the level of asthma control in asthma patients attending routine consultation in public or private centers in the Middle East and North Africa (MENA) region. We report the results of patients from Saudi Arabia included in the ESMAA study.

Methods {#sec1-2}
=======

Study design {#sec2-1}
------------

ESMAA was a descriptive, epidemiological, cross-sectional study to assess the level of asthma control and explore the potential predictive factors associated with higher/lower control in asthma patients in the MENA region. In this report, data from Saudi patients were analyzed. GINA classification was considered for assessing asthma control level by the physician.\[[@ref16]\]

Data source {#sec2-2}
-----------

General practitioners and/or specialists (pulmonologists and/or allergists) in the public and the private sectors in Saudi Arabia collected data from asthma patients attending routine consultation visits between December 2014 and December 2015. Participating physicians were selected from a national database according to their willingness to participate in the study and their academic degree. Sociodemographic data, disease characteristics, and treatment-related data were collected by the physician through asking the patients directly, while asthma control test (ACT), Short Form-8 Health Survey (SF-8), and MMAS-4^©^ questionnaires were completed by the patients themselves.

Study population {#sec2-3}
----------------

We included patients older than 18 years who were diagnosed with asthma at least 12 months prior to enrollment in the study. Patients participating in another clinical trial, patients suffering from any psychiatric disorders or any other chronic respiratory disorders (except for rhinitis), patients consulted for an asthmatic attack during 4 weeks prior to enrollment, and pregnant women were excluded from the study. We obtained written informed consent from all participating patients.

Outcomes {#sec2-4}
--------

The primary outcome of this study is the level of asthma control among included patients. According to the GINA 2012 classification, patients were classified as having controlled, partly controlled, or uncontrolled asthma. [Table 1](#T1){ref-type="table"} describes 2012 GINA classification of current clinical control and future risk. We also used ACT questionnaire as a supportive endpoint for the GINA evaluation of asthma control.\[[@ref17]\]

###### 

2012 Global Initiative for Asthma classification of current clinical control and future risk\*

  A. Assessment of current clinical control (in a given week over the past 4 weeks) controlled                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------- ----------------------------- ------------------------------------------------------
  Daytime symptoms                                                                                                                                                                                                                                       None (≤2/week)   \>2/week                      ≥3 items of partly controlled asthmaPresent any week
  Limitation of activities                                                                                                                                                                                                                               None             Any                           
  Nocturnal symptoms/awakening                                                                                                                                                                                                                           None             Any                           
  Need for reliever/rescue treatment                                                                                                                                                                                                                     None (≤2/week)   \>2/week                      
  Lung function (PEF/FEV)                                                                                                                                                                                                                                Normal           \<80% (predicted or better)   
                                                                                                                                                                                                                                                                                                        
  B. Assessment of future risk (of exacerbations, instability, rapid decline in lung function, side effects)                                                                                                                                                                                            
  Features associated with increased risk of future adverse events include: Poor clinical control, frequent exacerbations in the past year, any admission to critical care for asthma, low FEV, exposure to cigarette smoke, and high-dose medications                                                  

\*Global Initiative for Asthma (GINA). The global strategy for asthma management and prevention. 2012. Available at: http://www.ginasthma.org (accessed 31 July 2014). *Major global guidelines for the management of asthma*. GINA=Global Initiative for Asthma, FEV=Forced expiratory volume, PEF=Peak expiratory flow

Adherence and QoL were evaluated using MMAS-4^©^ questionnaire and SF-8 QoL questionnaire, respectively.\[[@ref18][@ref19]\]

Statistical analysis {#sec2-5}
--------------------

The minimum sample size was calculated according to the asthma control (primary objective of the study), considering an accuracy degree between 2% and 5% and a type I risk α = 5%. The percentage of unemployable data and nonresponse to patient\'s questionnaire was estimated at 15%. The following equation was used: *N* = (1.96)^2^*p*~0~*q*~0~/*i*^2^ where "*p*~0~" is the percentage of patients whose asthma is well controlled, "*q*~0~" is 1 − *p*~0~ while "*i*" is the accuracy degree.

All enrolled patients with no protocol deviations were considered for analysis. Descriptive statistics were carried out considering and two-sided 95% confidence intervals (CI) that were calculated by the Wilson method.

Special software (Qualimetric Health Outcome Scoring Software, version 4.5) was used for calculating ACT scores and SF-8 scores including automatic handling of missing data.

Logistic regression was used to explore the potential predictive factors of asthma control.

Univariate logistic regression was conducted where asthma was either considered as controlled (including partly controlled cases) or uncontrolled. The following factors were tested using univariate logistic regression: age, gender, body mass index (BMI), educational level, professional situation, medical insurance coverage, presence of allergic rhinitis, presence of gastroesophageal reflux disease, relevant chronic diseases, smoking status, physical exercise, duration of asthma since diagnosis, asthma disease characteristics, and treatment in the past 6 months in addition to the adherence to treatment. Odds ratio (OR) with its 95% CI was calculated for each potential predictive factor. Factors found to have a significant effect in univariate regression (*P* \< 0.10) were included in a multivariate regression model considering a 0.10 level of significance.

ACT scores and SF-8 scores were compared between asthma control levels (as per the GINA classification) using an analysis of variance test as appropriate, while adherence to treatment was compared between asthma control levels using a Chi-square test.

All statistical tests were two-sided, and *P* \< 0.05 was considered statistically significant.

Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, USA).

Results {#sec1-3}
=======

Baseline characteristics {#sec2-6}
------------------------

A total of 1030 asthma patients were enrolled in the study, of which 1009 met the eligibility criteria and were included in the analysis. The mean (±standard deviation \[SD\]) age was 48.7 years (±15.9). Females constituted 65.3% of the sample. The mean (±SD) BMI was 30.7 kg/m^2^(±7.4). [Table 2](#T2){ref-type="table"} describes sociodemographic characteristics of included patients. The mean (±SD) duration since diagnosis was 13.2 (±11.2) years. Other disease-related characteristics are described in [Table 3](#T3){ref-type="table"}.

###### 

Sociodemographic characteristics

  Characteristic                            *n* (%)
  ----------------------------------------- ------------
  Age                                       
   18-35                                    222 (22.0)
   35-55                                    425 (42.1)
   55-70                                    260 (25.8)
   ≥70                                      102 (10.1)
  Sex                                       
   Male                                     350 (34.7)
   Female                                   659 (65.3)
  BMI (kg/m^2^)                             
   \<18                                     17 (1.7)
   18-25                                    189 (19.1)
   25-30                                    306 (30.9)
   \>30                                     479 (48.3)
  Level of education                        
   Cannot read and write                    207 (20.5)
   Primary                                  202 (20.0)
   Secondary school                         276 (27.4)
   University degree                        279 (27.7)
   Higher education                         44 (4.4)
  Professional situation                    
   Active                                   386 (38.3)
   Nonactive                                622 (61.7)
  Medical insurance coverage                
   Yes                                      666 (66.2)
   No                                       340 (33.8)
  Smoking status                            
   Nonsmoker                                820 (86.5)
   Past smoker                              75 (7.9)
   Active smoker                            53 (5.6)
  Regular physical exercise                 
   Yes                                      618 (61.4)
   No                                       389 (38.6)
  Comorbidities (several answers allowed)   
   Allergic rhinitis                        529 (52.4)
   Gastroesophageal reflux                  251 (24.9)
   Hypertension                             163 (16.2)
   Diabetes                                 141 (14.0)
   Other (after reclassification)           111 (11.0)
   Dyslipidemia                             47 (4.7)
   Thyroid disorder                         44 (4.4)
   Related chronic disease                  31 (3.1)
   Cardiovascular disease                   22 (2.2)
   Allergic disease                         17 (1.7)
   Musculoskeletal disease                  11 (1.1)
   Obesity                                  7 (0.7)

BMI=Body mass index

###### 

Disease-related characteristics

  Characteristic                                                                 *n* (%)
  ------------------------------------------------------------------------------ ------------
  Asthma diagnosis history (years)                                               
   ≤2                                                                            109 (10.8)
   2-5                                                                           201 (19.9)
   \>5                                                                           699 (69.3)
  Frequency of symptoms in the last 6 months                                     
   Symptoms less than once per week                                              540 (54.2)
   Symptoms more than once per week and less than once per day                   333 (33.4)
   Symptoms on a daily basis                                                     123 (12.3)
  Mild exacerbation                                                              
   Yes                                                                           663 (65.7)
   No                                                                            346 (34.3)
  Exacerbation likely to affect activities and sleep                             
   Yes                                                                           187 (18.5)
   No                                                                            822 (81.5)
  Frequent exacerbation                                                          
   Yes                                                                           75 (7.4)
   No                                                                            934 (92.6)
  Nighttime symptoms (several answers allowed)                                   
   No more than twice per month                                                  633 (62.7)
   More than twice per month                                                     159 (15.8)
   More than once per week                                                       112 (11.1)
   Frequent nighttime symptoms                                                   124 (12.3)
   Short-acting B2 agonist use daily                                             39 (3.9)
   Physical activity limited                                                     45 (4.5)
  Spirometry                                                                     
   PEF ≤60% of predicted value                                                   141 (19.7)
   PEF 60-80% of predicted value                                                 254 (35.5)
   PEF ≥80% of predicted value                                                   320 (44.8)
  Asthma treatment reported during the past 6 months (several answers allowed)   
   Inhaled corticosteroids                                                       197 (19.6)
   Long-acting bronchodilator                                                    90 (9.0)
   Oral corticosteroids                                                          76 (7.6)
   Fixed combination (inhaled corticosteroids + long-acting beta-agonist)        833 (82.9)
   Antileukotrienes                                                              367 (36.5)
   Theophylline                                                                  55 (5.5)
   Anticholinergic bronchodilator                                                96 (9.6)
   Short-acting beta-agonist                                                     546 (54.3)
   Nasal corticosteroids                                                         41 (4.1)
   Antihistamine                                                                 12 (1.2)
   Other                                                                         83 (8.3)

PEF=Peak expiratory flow

Level of asthma control, quality of life, and adherence to treatment {#sec2-7}
--------------------------------------------------------------------

A total of 993 were evaluable by the GINA classification for asthma control. Less than one-third of the patients (30.1%) (95% CI: 27.3%--33.0%) was found to have controlled asthma and 31.9% (95% CI: 29.1%--34.9%) were found to have partly controlled asthma, while 38.0% (95% CI: 35.0%--41.0%) were found to have uncontrolled asthma. [Table 4](#T4){ref-type="table"} shows the assessment of future risk of included patients and ongoing asthma medications according to the GINA classification.

###### 

Assessment of future risks and ongoing asthma treatment according to the current clinical asthma control according to the Global Initiative for Asthma

                                                                                                Controlled (*n*=299)   Partly controlled (*n*=317)   Uncontrolled (*n*=377)   Total (*n*=993)
  --------------------------------------------------------------------------------------------- ---------------------- ----------------------------- ------------------------ -----------------
  Predictive characteristics of an increased risk of adverse events (several answers allowed)                                                                                 
   No predictive characteristics of increased risk of adverse events ticked                     50 (16.7)              39 (12.3)                     25 (6.6)                 114 (11.5)
   Poor clinical control                                                                        78 (26.1)              96 (30.3)                     200 (53.1)               374 (37.7)
   Exposure to cigarette smoke                                                                  84 (28.1)              47 (14.8)                     34 (9.0)                 165 (16.6)
   Frequent exacerbations in past year                                                          67 (22.4)              67 (21.1)                     63 (16.7)                197 (19.8)
   Low FEV/PEF                                                                                  14 (4.7)               38 (12.0)                     39 (10.3)                91 (9.2)
   High-dose medications                                                                        45 (15.1)              57 (18.0)                     36 (9.5)                 138 (13.9)
   Number of admission to critical care for asthma                                              7 (2.3)                3 (0.9)                       4 (1.1)                  14 (1.4)
  Ongoing asthma treatment reported at the time of the study (several answers allowed)                                                                                        
   Inhaled corticosteroids                                                                      56 (18.9)              49 (15.5)                     68 (18.1)                175 (17.4)
   Long-acting bronchodilator                                                                   23 (7.8)               22 (6.9)                      34 (9.0)                 79 (7.9)
   Oral corticosteroids                                                                         10 (3.4)               12 (3.8)                      28 (7.4)                 50 (5.0)
   Fixed combination (inhaled corticosteroids + long-acting beta-agonist)                       202 (68.2)             243 (76.7)                    310 (82.4)               767 (76.3)
   Antileukotrienes                                                                             59 (19.9)              97 (30.6)                     169 (44.9)               329 (32.7)
   Theophylline                                                                                 9 (3.0)                11 (3.5)                      30 (8.0)                 50 (5.0)
   Anticholinergic bronchodilator                                                               16 (5.4)               26 (8.2)                      44 (11.7)                86 (8.6)
   Short-acting beta-agonist                                                                    165 (55.7)             153 (48.3)                    179 (47.6)               511 (50.8)
   Nasal corticosteroids                                                                        13 (4.4)               14 (4.4)                      14 (3.7)                 41 (4.1)
   Antihistamine                                                                                4 (1.4)                0 (0.0)                       6 (1.6)                  10 (1.0)
   Other                                                                                        14 (4.7)               14 (4.4)                      26 (6.9)                 54 (5.4)

PEF=Peak expiratory flow, FEV=Forced expiratory volume

The mean (±SD) ACT score of these patients was 17.1 (±4.6) showing significant higher values among patients with better asthma control levels according to the GINA 2012 classification (*P* \< 0.001). Patients with controlled asthma (30.1%) showed the highest mean (±SD) ACT score (20.1 ± 3.4), while the mean (±SD) score of patients with partly controlled asthma (31.9%) was 18.4 (±3.7). The mean (±SD) ACT score was lowest (13.7 ± 3.9) in patients with uncontrolled asthma (37.9%).

QoL was measured according to the SF-8 questionnaire. All SF-8 scores in the controlled patients group were significantly higher than the scores of the other groups (*P* \< 0.001). Detailed results are shown in [Table 5](#T5){ref-type="table"}.

###### 

Short Form-8 Health Survey questionnaire^a^: Subscores and component summary scores according to the investigator assessment of current clinical asthma control according to the Global Initiative for Asthma

                               Mean±SD    *P*^b^                            
  ---------------------------- ---------- ---------- ----------- ---------- ---------
  Physical functioning         44.8±7.7   42.4±7.8   36.9±8.1    41.0±8.6   \<0.001
  Role physical                45.1±8.1   43.4±8.6   37.1±8.5    41.5±9.1   \<0.001
  Bodily pain                  51.4±8.5   47.9±9.3   43.3±9.2    47.2±9.6   \<0.001
  General health               49.2±6.8   47.1±7.1   42.0±7.6    45.8±7.8   \<0.001
  Vitality                     48.8±8.1   47.4±8.3   44.4±8.3    46.7±8.5   \<0.001
  Social functioning           47.0±8.3   45.7±8.9   40.8±9.4    44.2±9.3   \<0.001
  Role emotional               45.4±7.4   44.4±8.0   40.2±8.2    43.1±8.2   \<0.001
  Mental health                46.5±8.9   44.9±9.3   41.2±9.7    44.0±9.6   \<0.001
  Physical component summary   47.5±7.7   44.6±8.1   37.8±8.5    42.9±9.1   \<0.001
  Mental component summary     47.3±9.2   46.0±9.3   41.8±10.2   44.8±9.9   \<0.001

^a^Results are expressed as scores which range from 0 to 100; 100 indicates the highest level of QoL, ^b^*P* value of analysis of variance. SD=Standard deviation, QoL=Quality of life

When calculating treatment adherence (according to MMAS-4^©^ questionnaire), 27.4% of patients with controlled asthma showed good adherence, while 21.1% of patients with partly controlled asthma and 21.5% of patients with uncontrolled asthma showed good adherence with no significant difference of treatment adherence between the three groups (*P* = 0.112).

Predictive factors of asthma control {#sec2-8}
------------------------------------

In a univariate analysis comparing the pooled partially/completely controlled population versus the uncontrolled population, no significant difference was found between age groups (*P* = 0.550) or BMI groups (*P* = 0.107). Females were less likely to have controlled asthma than males (OR: 0.71 \[95% CI: 0.54--0.93\]). Regarding educational level, patients with higher education were almost four times more likely to have controlled asthma when compared to patients with less education (OR: 3.72 \[95% CI: 1.74--7.92\]). Patients without medical insurance coverage were more likely to have controlled asthma (OR: 1.44 \[95% CI: 1.09--1.90\]). Interestingly, nonsmokers did not show any significant difference in asthma control levels when compared to active smokers and past smokers (*P* = 0.824).

The ongoing use of inhaled corticosteroids, long-acting bronchodilators, and/or short-acting beta-agonists was not associated with a significant difference in level of asthma control (*P* = 0.699, *P* = 0.339, and *P* = 0.193, respectively).

In addition, patients using fixed combination (inhaled corticosteroids + long-acting beta-agonist) and those using antileukotrienes were more likely to have controlled asthma compared to patients not taking such medications (OR: 1.77 \[95% CI: 1.29--2.44\] and OR: 2.39 \[95% CI: 1.82--3.14\], respectively).

Discussion {#sec1-4}
==========

The lack of sufficient data on asthma control in the Middle East, generally, and in Saudi Arabia, specifically, highlights a clear need for uniform and thorough data on asthma control in this geographical region. Our study addressed this issue and confirmed the largely inadequate asthma control in Saudi Arabia on a large sample of asthma patients.

Our analysis of 1009 adult asthma patients in Saudi Arabia, who were diagnosed at least 12 months prior to enrollment in the study, showed only 30.1% (95% CI \[27.3%--33.0%\]) of patients to have controlled asthma (according to the GINA classification).

Patients with controlled asthma had higher ACT scores (*P* \< 0.001) and better QoL according to SF-8 questionnaire (*P* \< 0.001). However, they did not show better medication adherence (according to MMAS-4^©^ score) when compared to other groups (*P* = 0.112).

A study published in 2015 on 260 Saudi patients showed that 31.9% of the sample had controlled asthma.\[[@ref13]\] This number is nearly similar to our results. Another study conducted in 1060 Saudi patients, published in 2008, showed 36% of patients to have well-controlled or completely controlled asthma (using ACT questionnaire).\[[@ref20]\] Another study conducted in Jordan on 255 patients showed 30.6% to have a well-controlled asthma (using ACT questionnaire).\[[@ref14]\] A Turkish study showed 50.5% of included asthma patients to have controlled asthma.\[[@ref21]\] Although it is considered low, reported control levels in our study were relatively better than a report from Asia-pacific countries were only 7.6% of the patients were well-controlled.\[[@ref10]\] Percentage of patients with well-controlled asthma was also lower in Latin America countries (7%) according to a study published in 2013.\[[@ref11]\] Moreover, a study conducted in 8000 European patients showed that only 20.1% of participants have a controlled asthma (according to the GINA classification).\[[@ref22]\] All these figures highlight that asthma control is an important issue because most asthma patients have suboptimal control of their disease.\[[@ref7]\]

Possible reasons for this low asthma control include failure in guidelines implementation, which emphasizes the need of more practical and homogenous guidelines for diagnosis and treatment.\[[@ref23]\]

Certainly, attempts to improve adherence to asthma medications have not been succeeding.\[[@ref12]\] Our study also showed low levels of adherence to treatment among included patients. However, we did not find adherence to be associated with different likelihood of having an uncontrolled disease (*P* = 0.112). In the overall results of ESMAA study, good medication adherence was found to be significantly associated with asthma control (*P* \< 0.001).\[[@ref15]\]

Our results showed better levels of asthma control to be associated with better QoL (*P* \< 0.001). Similar results were also reported in the previous studies where lower levels of asthma control were associated with less productivity and decreased functionality.\[[@ref10][@ref11]\]

Patients with higher levels of education in our study were shown to have a more likelihood of having a controlled asthma. These results are consistent with previous research that showed less education to be associated with inadequate control levels.\[[@ref11][@ref13][@ref20][@ref21]\]

Females in our study had significantly lower levels of asthma control than males; this is consistent with the previous studies.\[[@ref11][@ref13][@ref20]\] On the other hand, several studies did not find any association between gender and asthma control levels.\[[@ref14][@ref24]\]

Although cigarette smoking is a known risk factor for most respiratory diseases, our study did not find a significant association between uncontrolled asthma and active smoking. This may be due to the relatively low percentage of active smokers in our sample (5.6%). Turktas *et al*. observed similar findings regarding the relationship between smoking status and asthma control.\[[@ref21]\]

Limitation for this study can be the level of subjectivity associated with collected data. We did not address the factors leading to uncontrol in details. For example, the proper inhaler device technique is very important in optimum drugs delivery and therefore asthma control.

Al-Jahdali *et al*. documented in their study that improper asthma inhaler device technique is associated with poor asthma control;\[[@ref25]\] unfortunately, we did not check proper use of inhaler in this study; however, the large sample size and inclusion of patients from many specialized and general practitioner clinics across the Kingdom make its results more generalizable with the need for further studies to confirm our results.

Many studies have investigated asthma control in Saudi patients;\[[@ref13][@ref20]\] however, strengths of our epidemiological study are not only assessing the level of asthma control in the same population, but also looking for an association between asthma control and patients\' characteristics, QoL, and treatment adherence.

Conclusion {#sec1-5}
==========

We conclude that asthma control remains suboptimal among Saudi population. This needs huge efforts from health-care professionals and patients to achieve acceptable levels of asthma control.
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